EANM Poster: A New Platform for Imaging Alpha Emitting Radiopharmaceuticals in Preclinical Cancer Models

Advancing preclinical alpha therapy research through high-sensitivity SPECT imaging and quantitative biodistribution analysis.

Accurate imaging and quantification of alpha-emitting radiopharmaceuticals present unique challenges in preclinical development, particularly due to low administered activities, complex decay chains and daughter radionuclide redistribution.

In this study, Perceptive Discovery researchers evaluated the Alpha-SPECT™ Mini platform, combining high-sensitivity SPECT imaging with VivoQuant^® analysis to assess the biodistribution and pharmacokinetics of an actinium-225 (Ac-225)-labeled antibody in tumor-bearing mice.

By comparing longitudinal in vivo imaging with ex vivo gamma counting, researchers demonstrated the platform’s ability to quantify tumor uptake and biodistribution at low administered activities while investigating the redistribution of bismuth-213 (Bi-213).

These findings highlight the importance of advanced imaging technologies in generating the quantitative evidence needed to guide radiopharmaceutical development. Through integrated radiochemistry, preclinical imaging, biodistribution and dosimetry expertise, Perceptive Discovery helps sponsors anticipate development challenges and make informed decisions as therapies progress toward clinical translation.

What You’ll Learn:

• High-Sensitivity Alpha Imaging: How Alpha-SPECT™ enables longitudinal imaging and quantification of Ac-225-labeled radiopharmaceuticals at low administered activities.
• Quantitative Biodistribution Analysis: How in vivo SPECT imaging compares with ex vivo gamma counting to assess tumor uptake and pharmacokinetics.
• Daughter Radionuclide Redistribution: Key findings on Bi-213 relocation and the challenges of quantifying daughter radionuclides in vivo.